X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs VENUS REMEDIES - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. VENUS REMEDIES FRESENIUS KABI ONCO./
VENUS REMEDIES
 
P/E (TTM) x 22.1 -4.1 - View Chart
P/BV x 3.1 0.2 2,032.8% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   VENUS REMEDIES
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
VENUS REMEDIES
Mar-18
FRESENIUS KABI ONCO./
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs176126 139.8%   
Low Rs7961 128.5%   
Sales per share (Unadj.) Rs37.7301.8 12.5%  
Earnings per share (Unadj.) Rs5.1-24.9 -20.5%  
Cash flow per share (Unadj.) Rs6.72.5 264.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.5293.3 14.5%  
Shares outstanding (eoy) m158.2312.34 1,282.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.3 1,089.9%   
Avg P/E ratio x25.0-3.8 -664.6%  
P/CF ratio (eoy) x18.936.7 51.5%  
Price / Book Value ratio x3.00.3 938.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1351,154 1,745.1%   
No. of employees `0001.20.9 124.5%   
Total wages/salary Rs m703393 178.9%   
Avg. sales/employee Rs Th5,176.24,026.1 128.6%   
Avg. wages/employee Rs Th610.4425.0 143.6%   
Avg. net profit/employee Rs Th699.6-331.8 -210.8%   
INCOME DATA
Net Sales Rs m5,9633,724 160.1%  
Other income Rs m1823 80.0%   
Total revenues Rs m5,9813,747 159.6%   
Gross profit Rs m1,430395 362.2%  
Depreciation Rs m258338 76.2%   
Interest Rs m-26354 -7.3%   
Profit before tax Rs m1,216-275 -441.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m34232 1,082.9%   
Profit after tax Rs m806-307 -262.6%  
Gross profit margin %24.010.6 226.2%  
Effective tax rate %28.1-11.5 -245.1%   
Net profit margin %13.5-8.2 -164.0%  
BALANCE SHEET DATA
Current assets Rs m5,1022,638 193.4%   
Current liabilities Rs m2,3852,305 103.5%   
Net working cap to sales %45.68.9 509.4%  
Current ratio x2.11.1 186.9%  
Inventory Days Days150135 110.8%  
Debtors Days Days11346 244.5%  
Net fixed assets Rs m5,1484,871 105.7%   
Share capital Rs m158123 128.2%   
"Free" reserves Rs m6,5563,496 187.5%   
Net worth Rs m6,7323,619 186.0%   
Long term debt Rs m9521,374 69.3%   
Total assets Rs m10,3887,509 138.3%  
Interest coverage x-45.80.2 -20,530.1%   
Debt to equity ratio x0.10.4 37.2%  
Sales to assets ratio x0.60.5 115.7%   
Return on assets %7.50.6 1,189.3%  
Return on equity %12.0-8.5 -141.2%  
Return on capital %14.61.6 923.0%  
Exports to sales %74.50-   
Imports to sales %24.813.9 178.6%   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477517 286.0%   
Fx inflow Rs m5,2980-   
Fx outflow Rs m1,772517 343.1%   
Net fx Rs m3,525-517 -682.6%   
CASH FLOW
From Operations Rs m1,274514 247.7%  
From Investments Rs m-1,204-123 978.2%  
From Financial Activity Rs m-196-387 50.7%  
Net Cashflow Rs m-1264 -3,007.1%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.2 166.7%  
FIIs % 9.6 0.6 1,655.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 66.4 13.7%  
Shareholders   42,599 20,121 211.7%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   IPCA LABS  NOVARTIS  ALEMBIC PHARMA  MERCK LTD  SANOFI INDIA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS